Literature DB >> 25756844

Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.

Søren L Kristensen1, Pardeep S Jhund, Lars Køber, David Preiss, John Kjekshus, Robert S McKelvie, Michael R Zile, Inder S Anand, John Wikstrand, Hans Wedel, Michel Komajda, Peter E Carson, John G F Cleland, John J V McMurray.   

Abstract

AIMS: To investigate the prognostic significance of hospitalization for worsening heart failure (WHF), myocardial infarction (MI), and stroke in patients with chronic heart failure (HF). METHODS AND
RESULTS: We studied 5011 patients with HF and reduced EF (HF-REF) in the CORONA trial and 4128 patients with HF and preserved EF (HF-PEF) in the I-Preserve trial. Adjusted hazard ratios (HRs) for death were estimated for 0-30 days and ≥31 days after first post-randomization WHF, MI, or stroke used as a time-dependent variable, compared with patients with none of these events. In CORONA, 1616 patients (32%) had post-randomization first events (1223 WHF, 216 MI, 177 stroke), and the adjusted HR for mortality ≤30 days after an event was: WHF 7.21 [95% confidence interval (CI) 2.05-25.40], MI 23.08 (95% CI 6.44-82.71), and stroke 32.15 (95% CI 8.93-115.83). The HR for mortality at >30 days was: WHF 3.62 (95% CI 3.11-4.21), MI 4.41 (95% CI 3.23-6.02), and stroke 3.19 (95% CI 2.21-4.61). In I-Preserve, 896 patients (22%) experienced a post-randomization event (638 WHF, 111 MI, 147 stroke). The HR for mortality ≤30 days was WHF 31.77 (95% CI 7.60-132.81), MI 154.77 (95% CI 34.21-700.17), and stroke 223.30 (95% CI 51.42-969.78); for >30 days it was WHF 3.36 (95% CI 2.79-4.05), MI 3.29 (95% CI 2.14-5.06), and stroke 5.13 (95% CI 3.61-7.29).
CONCLUSIONS: In patients with both HF-REF and HF-PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Clinical trials; HF‐PEF; HF‐REF; Heart failure; Mortality

Mesh:

Year:  2014        PMID: 25756844     DOI: 10.1002/ejhf.211

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

1.  Apelin ameliorated acute heart failure via inhibiting endoplasmic reticulum stress in rabbits.

Authors:  Yanqing Li; Haohan Lu; Wenyuan Xu; Yuxuan Shang; Cece Zhao; Yipu Wang; Rui Yang; Sheng Jin; Yuming Wu; Xiaoning Wang; Xu Teng
Journal:  Amino Acids       Date:  2021-02-20       Impact factor: 3.520

2.  Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.

Authors:  Nicolas Girerd; John Cleland; Stefan D Anker; William Byra; Carolyn S P Lam; David Lapolice; Mandeep R Mehra; Dirk J van Veldhuisen; Emmanuel Bresso; Zohra Lamiral; Barry Greenberg; Faiez Zannad
Journal:  Sci Rep       Date:  2022-05-20       Impact factor: 4.996

3.  Development and Validation of a Risk Score in Chinese Patients With Chronic Heart Failure.

Authors:  Maoning Lin; Jiachen Zhan; Yi Luan; Duanbin Li; Yu Shan; Tian Xu; Guosheng Fu; Wenbin Zhang; Min Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-11

4.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 5.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

6.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

7.  Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.

Authors:  John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2017-04-28       Impact factor: 15.534

8.  Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people.

Authors:  Stefan Koudstaal; Mar Pujades-Rodriguez; Spiros Denaxas; Johannes M I H Gho; Anoop D Shah; Ning Yu; Riyaz S Patel; Chris P Gale; Arno W Hoes; John G Cleland; Folkert W Asselbergs; Harry Hemingway
Journal:  Eur J Heart Fail       Date:  2016-12-23       Impact factor: 15.534

9.  Non-invasive telemedical care in heart failure patients and stroke: post hoc analysis of TIM-HF and TIM-HF2 trials.

Authors:  Serdar Tütüncü; Marcus Honold; Kerstin Koehler; Oliver Deckwart; Friedrich Koehler; Karl Georg Haeusler
Journal:  ESC Heart Fail       Date:  2020-03-12

10.  Mortality from Heart Failure with Mid-Range Ejection Fraction.

Authors:  Giovanni Possamai Dutra; Bruno Ferraz de Oliveira Gomes; Plínio Resende do Carmo Júnior; João Luiz Fernandes Petriz; Emilia Matos Nascimento; Basilio de Bragança Pereira; Gláucia Maria Moraes de Oliveira
Journal:  Arq Bras Cardiol       Date:  2022-04       Impact factor: 2.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.